The North American Malignant Hyperthermia Registry

MALIGNANT HYPERTHERMIA BIOPSY and

DIAGNOSTIC CONSULTATION REPORT

INSTRUCTIONS FOR USE

This form is only to be used by the staff of an MH diagnostic center.

- **1.** Use this form for each patient referred to you for MH evaluation, if they undergo muscle biopsy.
- 2. If any adult relatives wish to be registered by name, separate consent forms for participation in the Registry must be signed by that relative. If you wish to register a minor under the age of 18, a consent form must be signed by one of the minor's parent or guardian.
- **3.** The Center Director must review and sign this form verifying accuracy before it is submitted to the Registry.
- 4. Please make a photocopy of the completed form for your records.
- Submit original completed form to: The North American Malignant Hyperthermia Registry University of Florida Department of Anesthesiology 1600 SW Archer Road, PO Box 100254 Gainesville, FL 32610

I certify that the information contained in this report is complete and accurate.

Biopsy Center Director Signature

year month day

MH BIOPSY AND DIAGNOSTIC CONSULTATION REPORT

Version 9.6 May 2014

Complete this form for each patient referred for MH susceptibility evaluation. The MH muscle biopsy center director must review the completed form before it is returned to the NAMHR.

1. MH muscle biopsy center code number: *see final page for code numbers*

PATIENT IDENTIFICATION

- 2. North American MH Registry Number for this patient (if previously assigned)
- 3. Any previous North American MH Registry numbers associated with the patient. That is, AMRA, RSR, (formerly AKA), close relative's reports, etc.
 - a. _____ Comment

- b. _____ Comment
- c. _____ Comment

4. Patient's Initials

first middle last

- 5. Has consent been obtained to enter patient's name into the Registry? *check one*
 - () yes
 - () no

If yes, please complete a-g on following page.

Note: DO NOT COMPLETE IF CONSENT HAS NOT BEEN OBTAINED

a. Patient's name. This is the primary subject

last

first

middle

b.	Patient's previous name		
	last	first	middle
c.	Patient's maiden name	last	
d.	Patient's Address		
	street address		
	city	state/province	zip/postal code
	country	_	
e.	Phone number (<i>Home</i>) () (<i>Work</i>) ()	-	
f.	Patient e-mail address		
g.	Date of patient's birth		
year	\\\\		
DEMOGRA	PHIC INFORMATION		
 6. Sex chec () male () female 	k one		

7. Weight

_____ kilograms OR _____ lbs

8. Height _____ cms_OR _____ ft ____ inches

- 9. Year of patient's birth
- 10. Race:
 - check as many as apply
 - () Caucasian
 - () Hispanic
 - () African-American
 - () Native American
- () East Asian() South Asian

() African

- () Middle Eastern
- () Hawaiian or Pacific Islander
- () other (*specify*):_____

11. Body Build

cł	ieck one		
() Normal	() L	ean
() Muscular	()0	bese
() Postpartum		
() Other (specify):		

12. State or province of patient's residence

FAMILY IDENTIFICATION

- 13. Does the primary subject have minor children or siblings under the age of 6 and does this minor child's parent or guardian consent to the child being in the Registry? *check one*
- () yes


() no If yes, please complete below for all children under the age of 6

a. name



first

middle




year month day

Is this the child or the sibling of the biopsied patient?


- check one
- () child
- () sibling

b. name



() sibling

c. name



e. name

last	first	middle
Date of birth		
\ \	\	
year	month day	
Is this the child <i>check one</i>	or the sibling of the biopsied pa	atient?
() child		

14. Has consent been obtained to enter the names of children or siblings ages 6 through 17, or ages 18 and over, of the biopsied patient into the Registry?

<u>NOTE</u>: CONSENT MUST BE OBTAINED FROM EACH CHILD/SIBLING OVER 18 YEARS OF AGE FOR WHOM YOU ENTER THIS DATA (If the child/ sibling is deceased, the following data may be entered with the consent of the next of kin*. If the child is under 18 years of age, consent must be obtained from the child's parent or guardian).

* check your local/state regulations regarding the definition of next of kin

check one () yes

() no

If yes, complete below for all individuals for whom consent has been obtained

last

first

middle

Date of birth

year month day

Is this the child or the sibling of the biopsied patient?

- check one
- () child
- () sibling


b. name

last

first

middle

Date of birth



Has consent been obtained to enter the names of the parents of a biopsied patient?
 check one () yes
 () no

If yes, complete below

c.

d.

<u>NOTE</u>: CONSENT MUST BE OBTAINED FROM EACH PARENT FOR WHOM YOU ENTER THIS DATA (If the parent is deceased, the following data may be entered regardless of consent status.)

a. Mother of biopsied patient

	last	first	middle
	Date of mother's	birth	
year	\ \ \	 day	
	• 1		
Mother's ma	aiden name las		
Eather of hier	aciad nations		
Father of biop	sied patient		
	last	first	middle
	Date of father's b	irth	
	\\\\\\		
year	month	day	
•	History Table Family History table (1	pelow)	
Relation	nship to Patient	Known Medical Problem	18
a. child		1. fatal MH	
b. grandchild		2. survived fulminant M	H event
c. brother/siste	r	3. possible MH event	as only for those relatives with CUCT
d. half-sibling results)		4. MH family history (us	se only for those relatives with CHCT
e. niece/nephev	λ/	5. perioperative death - 1	not thought to be MH
f. mother		6. perioperative death - e	
g. maternal gra	ndparent	7. S.I.D.S. or cot death	
h. maternal aur		8. Sudden death - unkno	wn cause, age 1.5 to 45 yrs
j. maternal firs	t cousin	9. heat stroke	
k. maternal sec	ond cousin	10. neurolept malignant	syndrome
m. maternal - c	other	11. myopathy	
n. father		12. idiopathic creatine k	
o. paternal gra	-		igue and Immune Dysfunction Syndrome)
p. paternal aur		14. muscle pain, weakne	
q. paternal firs		15. episodic dark urine a	and muscle pain
r. paternal sec		16. diabetes	
s. paternal – o		17. none of the above	
t. relative by 1	narriage	18. unknown	

u. other blood relative

Please complete one row for each relative for whom relevant medical history is known.

Relative's <u>Initials</u>	Registry <u>Number</u> Leave blank if relative not registered. Insert "?" if relative registered but number not known	Relationship to Patient Select one letter from left-hand column above.	<u>Sex</u> M=Male F=Female	Medical <u>Problems</u> Select one or ore numbers from right-hand or column above.	CHCT <u>Test Result</u> Write "pos", "neg", "equiv", "unknown" "not performed", "other"	Genetic <u>Result</u> Specify familial mutation or "neg", "not performed", or "other"

FAMILY HISTORY

16a. Before this episode, was the patient's family history positive for: check all applicable

- () malignant hyperthermia
- () masseter spasm
- () intraoperative death <u>not</u> thought to be MH
- () sudden infant death syndrome or cot death
- () sudden death from unknown cause at < 45 year > 1.5 years
- () heatstroke
- () neurolept malignant syndrome
- () intolerance to heat
- () chronic muscle pain
- () frequent muscle cramps
- () chronic muscle weakness
- () exercise intolerance due to muscle pain, weakness or fever
- () episodes of dark urine and muscle pain
- () myopathies *specify type; write unknown if not known:*_____
- () idiopathic creatine kinase elevation

- () diabetes
 - () Type 1
 - () Type 2
- () none of the above
- () unknown
- () other specify _____

MEDICAL HISTORY

17. Does the patient have any of the following complaints?

check all applicable

- () muscle weakness interferes with daily activity at least once/week
- () muscle cramps interfere with daily activity at least once/week
- () cola colored urine
- () heat stroke or heat prostration
- () oral (or rectal/axillary equivalent) fever>38.6 ° C or 101.4 ° F at least 6 times/year without medical cause
- () recent generalized infection
 - If there was infection, how long ago was it? ____ (*days*)
- () recent use of cholesterol lowering drugs
- If so, which drug _____, and when was it last ingested? ___ (*days*)
- () a regular regimen of physical activity?
 - If so, when was the last work-out? ___ (*days*)
- () ingestion of any medicine to improve muscular performance
- () intolerance to heat
- () exercise intolerance due to muscle pain, weakness or fever
- () diabetes
 - () Type 1
 - () Type 2
- () other (*specify*)
- () none of the above
- () unknown
- 18. Has patient ever had physical findings of:

check all applicable

- () increased muscle tone
- () decreased muscle tone
- () generalized muscle weakness
- () myopathy specify type; write unknown if not known:
- () ptosis
- () strabismus
- () hiatal hernia
- () inguinal hernia
- () umbilical hernia

- () undescended testes
- () clubbed foot
- () joint hypermobility
- () kyphoscoliosis (moderate or severe; curve $>45^{\circ}$)
- () pectus carinatum
- () winged scapulae
- () skeletal fractures (more than 2)
- () gallstones
- () kidney stones
- () laryngeal papillomas
- () other (specify):_
- () none of the above
- () unknown

ANESTHETIC HISTORY

19. How many times was this patient anesthetized prior to this evaluation?

____ () unknown but > 0 () unknown Skip to question 35 if the response is zero

- 20. How many were general anesthetics?
 - () unknown but > 0 () unknown

21. Indicate the number of anesthetics with the following agents

- _____ volatile agents without succinylcholine
- _____ volatile agents with succinylcholine
- _____ succinylcholine without other known triggering agents
- 22. Year of most recent anesthetic (excluding present evaluation)
 _____ () unknown
- Were unusual metabolic responses noted during prior anesthetics?
 check one () yes
 () no

 - () unknown

23a. Were unusual metabolic or muscular responses noted during prior anesthetics? *check one* () no

- () yes
- () unknown

- 24. Was there delayed awakening from previous general anesthetics?
 - *check one* () yes
 - () no
 - () unknown

- 25. How many anesthetics were suspect for possible MH (director's opinion)?
- 26. How many fulminant MH episodes occurred (director's opinion)?

Skip to question 35 if the answer to questions 25 and 26 are zero
27. If the patient experienced possible or fulminant MH, answer questions a-w. Report the anesthetic that was most suspect for MH

a. Date of possible or fulminant MH episode: ______ ____ ____ _____
 year month day
 () unknown

NOTE: If consent for the patient has not been obtained only enter the year.

- b. Patient weight at time of incident _____kilograms OR ____lbs
- c. Height _____ cms OR ____ ft ____ inches
- d. State or province of patient's residence at time of incident.
- e. Location of incident

- i. Hospital ______ ii. City ______ iii. State or Province _____
- f. Type of procedure scheduled *check all applicable*
 - () cardiothoracic
 - () dental
 - () ear, nose, or throat
 - () eye
 - () general surgery
 - () laparoscopic surgery
 - a) abdominal
 - b) pelvic
 - c) other (specify)
 - () gynecology
 - () neurosurgery

- () thoracoscopic surgery (thoracic)
- () oral surgery
- () orthopedic
- () plastic surgery
- () radiology
- () obstetrics
- - () urology
 - () vascular

() transplant – Transplant type____

() unknown

() other (*specify*):_____

- g. Was the procedure an emergency?
 - check one
 - () yes
 - () no
 - () unknown
- g (a). Was the procedure performed outside a hospital? *check one*
 - () no
 - () yes
 - () ambulatory surgery center
 - () office
 - () unknown

g (b). Did this adverse reaction occur without exposure to anesthetic?

- check one
- () no
- () yes
- () unknown

g (c). Was the environment hot when this reaction occurred? *check one*

- песк опе
 - () no
 - () yes
 - If yes how hot? _____. ___ C or _____. ___ F

h. Was any infection present at the time of this surgery?

- check one () yes
 - () no
 - () unknown
- i. If infection was present, what organisms were known to be present?

j. Premedication and anesthetic agents utilized (before reaction occurred):

	check all applicable		
() sodium citrated citric acid (Bicitra)	() atropine	
() cimetidine (Tagamet)	() glycopyrrolate (Robinu	ıl)
() famotidine (Pepcid)		
() lansoprazole (Prevacid)		
() ranitidine (Zantac)	() scopolamine (Hyoscine	e)
() metoclopramide (Reglan)	() dolasetron (Anzemet)	
() omeprazole (Prilosec)	() droperidol (Inapsine)	

 () hydroxyzine (Vistaril) () ondansetron (Zofran) () promethazine (Phenergan) () diphenhydramine (Benedryl) () diphenhydramine (Benedryl) () clonidine (Duraclon) () clonidine (Duraclon) () dexmedetomide () rocuronium (Nimbex) () ketorolac (Toradol) () acetaminophen (Tylenol) () other NMB 				
 () promethazine (Phenergan) () diphenhydramine (Benedryl) () diphenhydramine (Benedryl) () atracurium (Tracrium) () clonidine (Duraclon) () clonidine	() hydroxy	yzine (Vistaril)		
 () diphenhydramine (Benedryl) () diphenhydramine (Benedryl) () atracurium (Tracrium) () clonidine (Duraclon) () clonidine (Duraclon) () clonidine (Duraclon) () cisatracurium (Nimbex) () dexmedetomide () rocuronium (Zemuron) () vecuronium (Norcuron) () () acetaminophen (Tylenol) () other NMB 	() ondanse	etron (Zofran)		() nalbuphine (Nubain)
 () clonidine (Duraclon) () clonidine (Duraclon) () dexmedetomide () rocuronium (Zemuron) () ketorolac (Toradol) () acetaminophen (Tylenol) () other NMB 	() prometh	nazine (Phenergan)		() naloxone (Narcan)
 () clonidine (Duraclon) () cisatracurium (Nimbex) () dexmedetomide () rocuronium (Zemuron) () ketorolac (Toradol) () vecuronium (Norcuron) () () acetaminophen (Tylenol) () other NMB 	() diphenh	ydramine (Benedryl)		
 () dexmedetomide () rocuronium (Zemuron) () ketorolac (Toradol) () acetaminophen (Tylenol) () other NMB 			() atracurium (Tracrium)
 () ketorolac (Toradol) () acetaminophen (Tylenol) () other NMB 	() clonidir	ne (Duraclon)	() cisatracurium (Nimbex)
 () acetaminophen (Tylenol) pancuronium (Pavulon) () other NMB 	() dexmed	letomide	() rocuronium (Zemuron)
() other NMB	() ketorola	ac (Toradol)	() vecuronium (Norcuron) ()
	() acetami	nophen (Tylenol)	р	ancuronium (Pavulon)
			() other NMB
() diazepam (Valium) () IM succinylcholine (Anectine)	() diazepa	m (Valium)	() IM succinylcholine (Anectine)
() lorazepam (Ativan) () IV succinylcholine (Anectine)	() lorazepa	am (Ativan)	() IV succinylcholine (Anectine)
() midazolam (Versed) () <i>NO</i> succinylcholine	() midazol	lam (Versed)		() NO succinylcholine
() edrophonium (Tensilon)			() edrophonium (Tensilon)
() etomidate (Amidate) () neostigmine (Prostigmin)	() etomida	ate (Amidate)	() neostigmine (Prostigmin)
() ketamine (Ketalar) () physostigmine (Antilirium)	() ketamin	ne (Ketalar)	() physostigmine (Antilirium)
() propofol (Diprivan)	() propofo	ol (Diprivan)		
() bupivacaine (Marcaine)			() bupivacaine (Marcaine)
() alfentanil (Alfenta) () levo-bupivacaine	() alfentar	nil (Alfenta)	() levo-bupivacaine
() fentanyl (Sublimaze) () choroprocaine (Nesacaine)	() fentany	l (Sublimaze)	() choroprocaine (Nesacaine)
() fentanyl and droperidol (Innovar) () cocaine	() fentany	l and droperidol (Innovar)	() cocaine
() meperidine (Demerol) () etidocaine (Duranest) ()	() meperic	line (Demerol)	() etidocaine (Duranest) ()
() morphine lidocaine (Xylocaine)	() morphi	ne	li	docaine (Xylocaine)
() remifentanyl (Ultiva) () mepivacaine (Carbocaine)	() remifen	tanyl (Ultiva)	() mepivacaine (Carbocaine)
() sufentanil (Sufenta) () prilocaine (Citanest) () procaine	() sufentar	nil (Sufenta)	() prilocaine (Citanest) () procaine
() hydromorphone (Dilaudid) (Novocain)	() hydrom	orphone (Dilaudid)	()	Novocain)
() ropivacaine (Naropin)	-	-	() ropivacaine (Naropin)
() unknown () tetracaine (Pontocaine)	() unknow	/n	() tetracaine (Pontocaine)
() NO potent volatile anesthetic	() N	O potent volatile anesthetic		
() sevoflurane (Ultane) () epinephrine			() epinephrine
() desflurane (Suprane) () ephedrine	() desflura	ane (Suprane)	() ephedrine
() isoflurane (Forane) () neosynephrine	() isoflura	nne (Forane)	() neosynephrine
() nitrous oxide	() nitrous	oxide		
() other (specify):	() other (<i>specify</i>):			

k. Anesthesia induction time

 $_$ _____ (in hours, express parts of an hour using decimal points) (example - 3 minutes = 0.05)

- 1. General anesthetic induction method *check one*
 - () inhalation

- () intravenous
- () other (*specify*):_____
- () not applicable

Anesthesia duration m.

(hours and minutes since induction)

Type of anesthetic prior to adverse metabolic or muscular reaction to anesthesia n.

- check all applicable
- () monitored anesthesia care (local standby)
- () regional anesthesia
- () spinal anesthesia
- () epidural anesthesia
- () general anesthesia **without** endotracheal intubation
- () general anesthesia with endotracheal intubation
- () tourniquet use
- () tourniquet use

elapsed time after the start of anesthesia tourniquet was inflated

_____ (hours and minutes since induction)

elapsed time after final release of tourniquet

_____ (hours and minutes since induction)

Patient Monitoring Utilized

Monitoring utilized (before reaction occurred): о. check all monitoring used

- () blood pressure monitor () end-tidal PCO₂
- () electrocardiograph
- () pulse oximeter

- () stethoscope
- () bladder (Foley) catheter
- () arterial catheter
- () central venous catheter
- () pulmonary artery catheter

temperature probes:

- () axillary
- () bladder
- () esophageal
- () nasopharyngeal
- () rectal
- () skin electronic
- () skin liquid crystal
- () tympanic
- () other monitoring (*specify*):_____

- p. If a liquid crystal temperature probe was used, did it accurately trend with core temperatures?
 - *check one* () yes
 - () no
- q. Was a forced air or I.V. warming device in use? *check one*
 - () yes
 - () no
 - () unknown

Documentation of the Reaction

r. Abnormal signs judged to be inappropriate by the attending anesthesiologist or other physician:

<u>RANK</u> in order of appearance. <u>NUMBER</u> do not check. <u>WRITE ZERO</u> if sign did not occur. (a number may be used more than once if signs were noted simultaneously)

- ____ masseter spasm: mouth cannot be fully opened but intubation possible
- ____ masseter spasm: teeth clamped shut, intubation via direct visualization impossible
- ____ generalized muscular rigidity
- ____ cola colored urine
- ____ tachypnea
- ____ hypercarbia
- ____ cyanosis
- ____ skin mottling
- ____ sinus tachycardia
- ____ ventricular tachycardia
- ____ ventricular fibrillation
- ____ elevated temperature
- _____ rapidly increasing temperature
- ____ sweating
- ____ excessive bleeding
- ____ hypertension > 20% of baseline
- ____ other (specify):_____
- s. Signs: Maximum values and times

fill in the blanks

_____ time first adverse sign noted (*after induction*)

(hours and minutes since induction)

- _____ time second adverse sign noted (*after induction*)
 - (hours and minutes since induction)

____ maximum temperature noted (°C) **OR**

_____ maximum temperature noted (°F)

_____ time maximum temperature noted (*after induction*)

(hours and minutes since induction)

 $_$ $_$ $_$ $_$ maximum end-tidal PCO₂ noted (mmHg)

_____ time maximum end-tidal PCO₂ noted (*after induction*)

(hours and minutes since induction)

t. Type of ventilation used at the time hypercarbia was first observed:

check one

- () spontaneous
- () assisted
- () controlled
- () not applicable
- () unknown
- u. Laboratory Evaluation used during the reaction. *Fill in the blanks for all lab tests obtained*

Most abnormal arterial blood gas after MH was suspected:

FiO ₂	-
pH	
PCO2	liters/minute ventilation at the time
PO ₂	of this blood gas.
BE (mEq/L) (specify ±)	
Bicarbonate (mEq/L)	
Time (<i>after induction</i>)	
(hours and minutes since	induction)
peak lactic acid	
mmol/L	
peak K ⁺	
m Eq/L or mmol/L	

peak post-op creatine kinase*	first creatine kinase*	last creatine kinase*
, U/L hours after induction	hrs after induction	hrs after induction
*(recommended intervals for o		
after adverse reaction)		

serum myoglobin

_____, ____ ng/ml _____hours after induction

urine myoglobin

_____, ____ mg/L _____ hours after induction

	T (prothrombin time) seconds	INR 	PTT (partial thromboplastin time) seconds
	aboratory upper limit o	of normal	laboratory upper limit of normal seconds
p] 	latelet count		fibrinogen mg/dl
	ing utilized (after reac heck all monitoring us	,	
(((((((((((((() blood pressure mon) electrocardiograph) stethoscope) arterial catheter) central venous cath) pulmonary artery c emperature probes:) axillary) bladder) esophageal) nasopharyngeal) rectal) skin – electronic) skin - liquid crystal) tympanic) other monitoring (s 	leter atheter	 () end-tidal PCO₂ () pulse oximeter () bladder (Foley) catheter
Treatmer check all	nt given for possible o <i>l treatments utilized;</i>) Volatile anesthetics ——·———) Anesthesia machin) Anesthesia circuit () Hyperventilation w) Dantrolene (type) () Dantrium () Revonto () Ryanodex ——·—	r fulminant MH <i>fill in the blanks</i> s discontinued Time (<i>after inductio</i> (<i>hours and minutes s</i> e changed changed	n) since induction)
		(hours and minutes s	· ·

v.

w.

_____ Total dose (mg) Time of last dose (*after induction*) _____ (hours and minutes since induction) () Active cooling () Fluid loading () Furosemide () Mannitol () Bicarbonate () Glucose, insulin () Amrinone () Bretylium () Vasopressor () Lidocaine () Procainamide () Defibrillation () CPR () other (specify) () none of the above

28. Mark any of the following that were noted after dantrolene was given:

- () Decrease in heart rate.
- () Decrease in end-tidal carbon dioxide or carbon dioxide tension in blood.
- () Decrease in temperature. If none were noted, please skip to question 35
- 29. How many minutes after dantrolene administration was the maximum decrease in this sign noted and what was the magnitude of this change?

Heart rate

(___) minutes

(__) (beats/min)

Carbon dioxide

```
(___) minutes
(__) (mmHg or torr)
Temperature
(___) minutes
(____°C) or (____°F)
```

30. Were any problems noted with the dantrolene administration?

check one

- () yes
 () no
 If no, please skip to question 32
- 31. What were the observed dantrolene complications? *check all applicable*
 - () phlebitis
 - () excessive secretions
 - () gastrointestinal upset
 - () hyperkalemia
 - () muscle weakness

() respiratory failure

- () other (*specify*):___
- 32. Did the patient develop additional signs or symptoms after initial adequate treatment (recrudescence)? *check one*
 - () yes
 - () no

If no, please skip to question 35

33. What was the time of the recrudescence?

____: ____ time (hours after anesthetic induction)

34. Signs of recrudescence that were noted:

(judged to be inappropriate by the attending anesthesiologist or other physician)

RANK in order of appearance.

(a number may be used more than once if signs were noted simultaneously)

- ____ masseter spasm: mouth cannot be fully opened but intubation possible
- ____ masseter spasm: teeth clamped shut, intubation via direct visualization impossible
- ____ generalized muscular rigidity
- ____ cola colored urine
- ____ tachypnea
- ____ hypercarbia
- ____ cyanosis
- ____ skin mottling
- ____ sinus tachycardia
- _____ ventricular tachycardia
- _____ ventricular fibrillation
- ____ elevated temperature
- _____ rapidly increasing temperature
- ____ sweating
- ____ excessive bleeding
- ____ hypertension > 20% of baseline
- ____ other (specify):___

ADVERSE METABOLIC REACTION TO ANESTHESIA (AMRA) REPORT

35. If an AMRA Report was submitted, did you review it after pertinent anesthesia records were obtained?

check one

- () yes
- () no

If no, skip to question 57

AMRA number (if known) ____ ___ ___ ___

36. Were errors found in the AMRA Report? *check one*() yes
() no

LABORATORY EXAM:

Serum Creatine Kinase

- 37. Creatine kinase at the time of evaluation:
- Laboratory upper limit of normal for creatine kinase
 U/L

Muscle Biopsy

- 39. Was a MH diagnostic muscle biopsy indicated? *check one*
 - () yes
 - () no
 - Note: If no, then skip to question 55

40. What was the reason for the MH diagnostic muscle biopsy?

check all applicable

- () fulminant MH
- () possible MH event (may include MMR), AMRA Report completed

- () possible MH event (may include MMR), AMRA Report not completed
- () family history of MH
- () control
- () negative genetic test
 - location _____
 - date

exons examined _____

- () other (*specify*):_____
- 41. Date of muscle biopsy

year month day

42. Time of anesthetic induction for muscle biopsy

_____: ____ (military time)

43. Time muscle was excised

____: ____ (military time)

- 44. Which muscle was biopsied?
 - check one
 - () vastus
 - () rectus abdominus
 - () gracilis
 - () other (*specify*):___

45. Were any medications being taken at the time of biopsy? *check one*

- eck one
- () yes
- () no

If yes, specify type of medication:

Type of agent	Name of Drug	Hrs. before biopsy
calcium channel blocker		
neuroleptic agent		
adrenergic agent		
lipid lowering agent		
other		

46. Premedication and anesthetic agents utilized (for biopsy): *check all applicable*

- () sodium citrated citric acid (Bicitra)
- () cimetidine (Tagamet)
- () famotidine (Pepcid)
- () lansoprazole (Prevacid)
- () ranitidine (Zantac)

() metoclopramide (Reglan)

- () omeprazole (Prilosec)
- () atropine
- () glycopyrrolate (Robinul)
- () scopolamine (Hyoscine)
- () dolasetron (Anzemet)
- () droperidol (Inapsine)
- () hydroxyzine (Vistaril)
- () ondansetron (Zofran)
- () promethazine (Phenergan)
- () diphenhydramine (Benedryl)

() clonidine (Duraclon)

- () dexmedetomidine
- () ketorolac (Toradol)
- () acetaminophen (Tylenol)
- () diazepam (Valium)
- () lorazepam (Ativan)
- () midazolam (Versed)
- () etomidate (Amidate)
- () ketamine (Ketalar)
- () propofol (Diprivan)
- () alfentanil (Alfenta)() fentanyl (Sublimaze)
- () fentanyl and droperidol
- (Innovar)
- () meperidine (Demerol)

() morphine () remifentanyl (Ultiva) () sufentanil (Sufenta) () hydromorphone (Dilaudid) () unknown () nitrous oxide () flumazenil (Romazicon) () nalbuphine (Nubain) () naloxone (Narcan) () atracurium (Tracrium) () cisatracurium (Nimbex) () rocuronium (Zemuron) () vecuronium (Norcuron) () pancuronium (Pavulon) () other NMB () **IM** succinylcholine (Anectine) () **IV** succinylcholine (Anectine) () NO succinylcholine () edrophonium (Tensilon) () other (*specify*):_____

- () neostigmine (Prostigmin)
- () physostigmine (Antilirium)
- () pyridostigmine (Mestinon)
- () bupivacaine (Marcaine)
- () levo-bupivacaine
- () choroprocaine (Nesacaine)
- () cocaine
- () etidocaine (Duranest)
- () lidocaine (Xylocaine)
- () mepivacaine (Carbocaine)
- () prilocaine (Citanest)
- () procaine (Novocain)
- () ropivacaine (Naropin)
- () tetracaine (Pontocaine)
- () epinephrine
- () ephedrine
- () neosynephrine

- 46a. Type of anesthetic used for biopsy: *check all applicable*
 - () monitored anesthesia care (local standby)
 - () regional anesthesia
 - () spinal anesthesia
 - () epidural anesthesia
 - () general anesthesia without endotracheal intubation
 - () general anesthesia with endotracheal intubation
 - () general anesthesia with a face mask
 - () general anesthesia with a laryngeal mask airway

HISTOLOGY

- 47. Was muscle histology performed? *check one*
 - () yes
 - () no

If no, skip to question 48

- 48. The muscle histology result was: *check one*
 - () normal
 - () abnormal
 - () equivocal

If normal, skip to question 48

49. What were the abnormal histologic findings?

check one

- () diffusely distributed internal nuclei
- () other (specify abnormality, write pending if results not available)
- 50. Was muscle histochemistry performed? *check one*
 - () yes
 - () no

If no, skip to question 51

- 51. The muscle histochemistry result was: *check one*
 - () normal
 - () abnormal
 - () equivocal If normal, skip to question 51

52. Specify results of muscle histochemistry:

check one

- () moth-eaten fibers
- () cores
- () other (specify abnormality, write pending if results not available)

CONTRACTURE TESTS

53. In your lab, when muscle is exposed to 3% halothane, what is the minimum contracture indicating MH susceptibility?

0. ____ grams

54. To date, how many control patients has this lab evaluated with the 1989 Biopsy Standards protocol?

55. MH Diagnostic Muscle Biopsy Results *check one*

- () positive -- MH susceptible
- () negative -- not susceptible to MH
- () equivocal -- MH susceptibility not determined
- () control biopsy

56. <u>Contracture Test Results</u>

HALOTHANE AT 3% (Required):	<u>Strip 1</u>	<u>Strip 2</u>	<u>Strip 3</u>
Hours between excision to completion of test (h)	·	_·	_·
Stimulation: duration (milliseconds) frequency (Hz) voltage (volts) current (mA)	 • •_	 • •_	 · ·_
Was a length/tension curve done? check one	() no () yes	() no () yes	() no () yes
Pre-drug twitch tension (g) (measure from baseline for twitch tension only)			•
Pre-drug tension 3% hal(g) Low point tension 3% hal(g)	· ·	· ·	·
Contracture tension developed to 3% hal(g)	·	·	·
Do you consider the tension developed to be abnormal? <i>check one</i>	() no () yes	() no () yes	() no () yes
Length (cm) Wet Weight (g)	_·	_· ·	_·

	<u>Strip 1</u>	<u>Strip 2</u>	<u>Strip 3</u>
CAFFEINE ALONE (Required):			
Hours between excision to completion			
of test (h)	_·	_·	•
Stimulation:			
duration (milliseconds)	_		
frequency (Hz)	•	•	•
voltage (volts)	•	·	•
current (mA)			
Was a length/tension curve done?			
check one	() no	() no	() no
	() yes	() yes	() yes
Pre-drug twitch tension (g)	·	·	·
(measure from baseline for twitch tension only)			
Predrug tension 0.5mM (g)	·	·	·
Plateau tension 0.5mM (g)	··	·	·
Predrug tension 1.0mM (g)		••	·_
Plateau tension 1.0mM (g)	· · ·		
(6)		* *	
Predrug tension 2.0mM (g)	•	•	•
Plateau tension 2.0mM (g)	·	·	·
Predrug tension 4.0mM (g)	·	·	·
Plateau tension 4.0mM (g)	•	•	·
Product tonsion 8.0mM (α)			
Predrug tension 8.0mM (g)	•	•	•
Plateau tension 8.0mM (g)	•	•	·
Predrug tension 32.0mM (g)	·	·	·
Plateau tension 32.0mM (g)	·	·	·
CSC (mM)	••	··	·
% response at 2mM	·	·	•

	<u>Strip 1</u>		<u>Strip 3</u>
Do you consider the tension developed to be abnormal? <i>check one</i>	() no	() no	() no
	() yes	() yes	() yes
If yes, at what concentration? If yes, at what CSC?			
If yes, at what % response?			
Length (cm) Wet Weight (g)	 	_· ·	_·
HALOTHANE 1% & CAFFEINE (Optional):	<u>Strip 1</u>	<u>Strip 2</u>	<u>Strip 3</u>
Hours between excision to completion of test (h)	_·	<u>-</u> -	_·
Stimulation:			
duration (milliseconds)			
frequency (Hz) voltage (volts)	•	_•_	•
current (mA)	·_	·_	·
Was a length/tension curve done?			
check one	() no () yes	() no () yes	() no () yes
Pre-drug twitch tension (g) (measure from baseline for twitch tension only)	·_		·
Pre-drug tension 1% hal(g)	·	·	·
Low point tension 1% hal(g)	·	·	·
Contracture tension developed to 1% hal(g)	·	·	·
Predrug tension 0.25mM (g)	·	·	•
Plateau tension 0.25mM (g)	·	·	·
Predrug tension 0.5mM (g)	·	·	·
Plateau tension 0.5mM (g)	·	·	·

Predrug tension 1.0mM (g)	<u>Strip 1</u>	<u>Strip 2</u>	<u>Strip 3</u>
Plateau tension 1.0mM (g)	·	·	· ·
Predrug tension 2.0mM (g)	·	·	·
Plateau tension 2.0mM (g)	·	·	·
Predrug tension 4.0mM (g)	·	·	·
Plateau tension 4.0mM (g)	·	·	·
Predrug tension 32.0mM (g)	·	·	·
Plateau tension 32.0mM (g)	·	·	·
HCSC (mM)	·	·	·
Do you consider the tension developed to be			
abnormal? check one	() no () yes	() no () yes	() no () yes
If yes, at what concentration?		() jes	()) 23
If yes, at what HCSC?			
Length (cm)	•	_·	·
Wet Weight (g) HALOTHANE AT 2% (<i>Optional</i>):	• <u>Strip 1</u>	•	• <u>Strip 3</u>
	<u>~~~</u>	<u></u>	<u></u>
Hours between excision to completion of test (h)	•	•	•
Stimulation: duration (milliseconds)			
frequency (Hz)		_·_	•
voltage (volts) current (mA)	·		
Was a length/tension curve done? <i>check one</i>	() n o	() no	() no
	() yes	() yes	() yes
Pre-drug twitch tension (g)	·	•	•
(measure from baseline for twitch tension only)			

	<u>Strip 1</u>	<u>Strip 2</u>	<u>Strip 3</u>
Pre-drug tension 2% hal(g)	·	·	·
Low point tension 2% hal(g)	·	·	·
Contracture tension developed to 2% hal(g)	·	·	·
Do you consider the tension developed to be ab	normal? check one		
-	() no	() no	() no
	() yes	() yes	() yes
Length (cm)	·	·	
Wet Weight (g)	•	•	•

TISSUE AND BLOOD STORAGE

57.	Has additional muscle tissue been stored?			
	check one			
	() yes			
	() no			
	If yes, specify Sample ID No:			
	Location			
58.	Has an additional blood specimen been stored? <i>check one</i>			
	() yes			
	() no			
	If yes, specify Sample ID No:			

DNA TESTING

Wa	s a genetic exam performed? <i>check one</i>	
	() yes () unknown () no	
WI	here was the genetic test done?	
Is	a sample of the DNA stored in the lab? () yes () no	
W	ten was the genetic test done?	
W	nich of the RYR1 exons were examined?	
W1	hich of the RYR1 exons were examined?	
WI		
		nť
	If unknown, check here ()	nť
Wa	If unknown, check here () us any mutation associated with MH or central core disease prese check one () yes () unknown () no	nt

- () no
 - If yes, specify _____

COMMENTS ON PATIENT (Optional)

Please mail original to:

The North American Malignant Hyperthermia Registry University of Florida Department of Anesthesiology 1600 SW Archer Road, PO Box 100254 Gainesville, FL 32610

MH BIOPSY CENTER CODE NUMBERS

Wake Forest University	06
Toronto General Hospital	05
University of California at Davis	07
Uniformed Services University	16
University of Minnesota	24